Navigation Links
Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes
Date:6/8/2011

ive RNAi therapeutic products for genetically defined diseases in advanced stages of clinical development by the end of 2015.  Alnylam has additional partner-based programs in clinical or development stages, including ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection, ALN-VSP for the treatment of liver cancers, and ALN-HTT for the treatment of Huntington's disease.  The company's leadership position on RNAi therapeutics and intellectual property have enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, and Cubist.  In addition, Alnylam and Isis co-founded Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics; Regulus has formed partnerships with GlaxoSmithKline and sanofi-aventis.  Alnylam has also formed Alnylam Biotherapeutics, a division of the company focused on the development of RNAi technologies for application in biologics manufacturing, including recombinant proteins and monoclonal antibodies.  Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 100 peer-reviewed papers, including many in the world's top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, and Cell.  Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts.  For more information, please visit www.alnylam.com.

Forward-Looking Statements

This press release includes forward-looking statements regarding the future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus, including statements regarding the therapeutic potential of targeting miR-103/107. Any statement describing Regulus' goals, expectations, financial or oth
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Brain Signature for Cigarette Cravings Identified
3. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
4. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
5. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
6. InVitrias Cellastim Showcased in Nature Article
7. InnoCentive and Nature Publishing Group Announce Partnership to Facilitate Open Innovation
8. Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures
9. Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women
10. Groundbreaking Study Published in Nature Biotechnology Demonstrates Sensitivity of Single Molecule Test for Detection of Prostate Cancer
11. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)...  Decision Resources Group finds that the laparoscopic device ... will increase to a value of over $4.3 billion ... in the large direct energy device market. In particular, ... due to the advantages they offer and as new ... Decision Resources Group,s coverage of the U.S. laparoscopic device ...
(Date:12/19/2014)... KANSAS CITY, Kan. , Dec. 18, 2014 ... PETX ), a biopharmaceutical company focused on ... for companion animals, today announced positive results from ... company,s innovative drug for treating pain in dogs ... demonstrated improvements in pain assessment scores that were ...
(Date:12/17/2014)... 17, 2014 Revenue and earnings above ... research and development In the past 2013/14 fiscal ... two percent to EUR 4.287 billion (last year: EUR 4.190 ... percent to EUR 360 million. "Overall, 2013/14 was a successful ... Kaschke , President and CEO of Carl Zeiss AG. "Thanks ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2
... SAN DIEGO , April 27 ResMed Inc. (NYSE: RMD ) ... , , ... Boston on May 4, 2010 ; Jefferies Global Life Sciences Conference ... ; William Blair Growth Stock Conference at the Four Seasons in Chicago ...
... 27 Volcano Corporation (Nasdaq: VOLC ), ... guidance tools designed to enhance the diagnosis and treatment ... it has entered into a distribution agreement with AngioScore ... indications in Japan . This is the first ...
Cached Medicine Technology:ResMed Inc. to Present at Upcoming Conferences 2Volcano Announces Distribution Agreement With AngioScore for the AngioSculpt(R) PTCA Scoring Balloon Catheter in Japan 2Volcano Announces Distribution Agreement With AngioScore for the AngioSculpt(R) PTCA Scoring Balloon Catheter in Japan 3Volcano Announces Distribution Agreement With AngioScore for the AngioSculpt(R) PTCA Scoring Balloon Catheter in Japan 4
(Date:12/19/2014)... December 20, 2014 Sweetdressy.com , ... has introduced its newest selection of cheap prom dresses ... very popular in the world and clients can buy ... Meanwhile, these prom dresses feature cool cuts and delicate ... now, targeting the middle-end market. Discount shipping costs are ...
(Date:12/19/2014)... December 19, 2014 SuperCloset raises the ... Rooms. SuperCloset continues to offer indoor growers the most ... of the new SuperClone Rooms with the award winning ... turnkey indoor hydroponic grow room setup. , The SuperClone ... SuperCloset’s SuperPonic SuperCloner 50 . The ...
(Date:12/19/2014)... The print component of Vision and Hearing is distributed ... Star, with a circulation of approximately 230,433 copies and ... distributed nationally through a vast social media strategy and ... outlets. To explore the digital version of the campaign, ... an exclusive interview with Mark DeMontis , sharing his ...
(Date:12/19/2014)... drug users who also use cocaine and amphetamines have ... users, a new study finds. "We know that ... attempt and completed suicide," Didier Jutras-Aswad, a psychiatry professor ... news release. "However, there are many different profiles of ... users were actually more likely to attempt suicide." ...
(Date:12/19/2014)... Diet Doc strives to continue to ... weight loss by combining scientific fast weight ... the company understand that remaining committed to a diet ... carbohydrates and sugars from the diet can cause patients ... weight loss goals. , For this reason, Diet ...
Breaking Medicine News(10 mins):Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 3Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 4
... , FRIDAY, Sept. 16 (HealthDay News) -- People ... clotting and inflammation have a lower five-year survival rate ... findings should be used to better treat and ensure ... said the research team from Duke University Medical Center ...
... GALVESTON, September 16, 2011 Researchers have shown for the ... cells by binding to and rendering inert protein p53, a ... of Texas Medical Branch may lead to treatments for a ... and appears in the current print issue of the ...
... has awarded $11.3 million to Case Western Reserve University ... for research on gastrointestinal cancers. The funding designates the ... in Gastrointestinal (GI) Cancers recognition extended to just ... is the primary affiliate of Case Western Reserve and ...
... WINSTON-SALEM, N.C. Sept. 16, 2011 A study ... colleagues suggests that a high intake of calcium causes ... absorbers of the mineral. "High dietary intake of ... the explanation for this observation has been elusive," said ...
... (USC) epidemiologists suggests that a high intake of calcium ... good absorbers of the mineral. "High dietary intake ... and this study suggests that these associations are likely ... professor of preventive medicine at the Keck School of ...
... highlight Pain Awareness Month in September, The ... interdisciplinary organization devoted to the field of aging is ... for seniors. Paired with its other recent research findings, ... advances in pain prevention, treatment, and management may improve care ...
Cached Medicine News:Health News:Gene Variant May Raise Death Risk After Heart Bypass 2Health News:Researchers identify potential molecular target to prevent growth of cancer cells 2Health News:National Cancer Institute establishes $11.3 million center at Case Western Reserve 2Health News:National Cancer Institute establishes $11.3 million center at Case Western Reserve 3Health News:National Cancer Institute establishes $11.3 million center at Case Western Reserve 4Health News:National Cancer Institute establishes $11.3 million center at Case Western Reserve 5Health News:National Cancer Institute establishes $11.3 million center at Case Western Reserve 6Health News:Genetics may explain why calcium increases risk for prostate cancer 2Health News:Genetics may predict why calcium increases risk for prostate cancer 2Health News:GSA sets focus on optimizing older adults' pain care 2
... super-light polypropylene mesh which offers an excellent ... considerably. Optilene Mesh LP is the alternative ... procedures. It perfectly conforms,to anatomical structures. Due ... adapts to the movements of the patient ...
... LP is a lightweight polypropylene mesh ... considerably reduced,foreign body reaction. The softer, ... It perfectly conforms to,anatomical structures. Due ... LP adapts to the movements of ...
... The Celsius Control System ... that can safely,and rapidly lower ... chosen target temperature and,rewarm patients ... Control System consists of an ...
... pump" coronary artery surgery is the latest ... is being embraced world-wide by increasing numbers ... subtle but reduced mortality, stroke, and bleeding ... benefits. A cardiac stabilizer is mandatory for ...
Medicine Products: